Telormedix, a Swiss clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, has appointed Nicholas Ralphe Rogerson as chairman.
Rogerson has worked in the pharmaceutical industry for nearly 25 years in major companies, as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues such as partnering, M&A and strategic exits.
Following an early scientific career, Rogerson started in regulatory affairs and progressed to business development. He has been global head of pharmaceutical business development at Hoffmann-La Roche, head of corporate M&A for Novartis and md of Bear Stearns, leading its European Pharma M&A efforts.
Telormedix appoints new chairman
Nicholas Rogerson has taken the role
You may also like
Design & Build
![Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics]()
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics
The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Manufacturing
![Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month]()
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month
Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Media
![FUJIFILM Biotechnologies lands three CPHI Pharma Award nominations for continuous manufacturing and precision purification]()
FUJIFILM Biotechnologies lands three CPHI Pharma Award nominations for continuous manufacturing and precision purification
The CDMO's MaruX platform, ShunzymeX purification technology and COO Maja Pedersen are all shortlisted ahead of its CPHI Milan appearance at booth 8A2, where senior leadership will present on Europe's biomanufacturing strategy
